Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report
Alexandria T M Lee, Cathleen June Park, Zhaohui Liao Arter, Misako Nagasaka, Sai-Hong Ignatius Ou · 2025
Read Incretin Receptor Agonist, Semaglutide, as a Treatment for Alectinib-Induced Excessive Weight Gain. A Case Report by Alexandria T M Lee, Cathleen June Park, Zhaohui Liao Arter, Misako Nagasaka, Sai-Hong Ignatius Ou (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12747890.txt.
Description
Alexandria Lee and co-authors report a case in 2025 of a cancer drug for weight gain, used to treat weight gain caused by another cancer drug. The first drug targets a gene fault in lung cancer and is a first choice for advanced cases. It is seen as well tolerated, but reports now show it can also cause marked weight gain, like a newer rival drug known for that effect.
Their patient gained excess weight while on the lung drug. The team treated the gain with a hormone based drug first made for diabetes and weight care. The case follows how the weight and the cancer care evolved under that add on. A case like this gives clinics a first map for a side effect that can harm health and make patients want to quit a drug that is keeping cancer at bay.
Catalog record
| CREATOR | Alexandria T M Lee, Cathleen June Park, Zhaohui Liao Arter, Misako Nagasaka, Sai-Hong Ignatius Ou |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 11 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |